(0.33%) 5 117.04 points
(0.33%) 38 365 points
(0.37%) 15 987 points
(-0.94%) $83.06
(5.56%) $2.03
(0.34%) $2 355.10
(0.46%) $27.66
(4.05%) $959.40
(-0.25%) $0.932
(-0.44%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology...
Stats | |
---|---|
本日の出来高 | 585 786 |
平均出来高 | 1.28M |
時価総額 | 35.08M |
EPS | $0 ( 2024-03-18 ) |
次の収益日 | ( $-0.250 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.040 |
ATR14 | $0.00300 (0.44%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Grant Stuart M. | Buy | 100 000 | Common stock, par value $0.0001 |
2024-03-19 | Grant Stuart M. | Buy | 50 000 | Common stock, par value $0.0001 |
2024-03-08 | Grant Stuart M. | Buy | 10 717 | Common stock, par value $0.0001 |
2024-02-12 | Gandolfo John P | Buy | 60 000 | Stock Option (right to buy) |
2024-02-12 | Rowe Michael M | Buy | 75 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
69.07 |
Last 95 transactions |
Buy: 2 919 948 | Sell: 334 000 |
ボリューム 相関
Eyenovia Inc 相関
10 最も正の相関 | |
---|---|
WINA | 0.968 |
INZY | 0.966 |
AMTBB | 0.961 |
CSPI | 0.955 |
TAYD | 0.95 |
SVFAU | 0.948 |
SVFA | 0.947 |
HROW | 0.946 |
BRLI | 0.944 |
HSKA | 0.944 |
10 最も負の相関 | |
---|---|
CYRN | -0.957 |
TLGT | -0.936 |
GNTY | -0.935 |
FVCB | -0.934 |
ONEM | -0.933 |
RPRX | -0.93 |
PEAR | -0.93 |
VORB | -0.929 |
BWB | -0.929 |
AROW | -0.927 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Eyenovia Inc 相関 - 通貨/商品
Eyenovia Inc 財務諸表
Annual | 2023 |
収益: | $3 787.00 |
総利益: | $-783 208 (-20 681.49 %) |
EPS: | $-0.660 |
FY | 2023 |
収益: | $3 787.00 |
総利益: | $-783 208 (-20 681.49 %) |
EPS: | $-0.660 |
FY | 2022 |
収益: | $0 |
総利益: | $-307 430 (0.00 %) |
EPS: | $-0.820 |
FY | 2021 |
収益: | $14.00M |
総利益: | $12.40M (88.57 %) |
EPS: | $-0.607 |
Financial Reports:
No articles found.
Eyenovia Inc
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。